WallStSmart

Merck & Company Inc (MRK)vsQuidel Corporation (QDEL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 2375% more annual revenue ($65.77B vs $2.66B). MRK leads profitability with a 13.6% profit margin vs -45.6%. QDEL appears more attractively valued with a PEG of 2.06. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 3.3Quality: 4.8
Piotroski: 2/9

QDEL

Hold

40

out of 100

Grade: D

Growth: 2.0Profit: 2.5Value: 6.3Quality: 4.8
Piotroski: 5/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKOvervalued (-14.9%)

Margin of Safety

-14.9%

Fair Value

$97.76

Current Price

$111.38

$13.62 premium

UndervaluedFair: $97.76Overvalued
QDELUndervalued (+89.6%)

Margin of Safety

+89.6%

Fair Value

$276.19

Current Price

$10.80

$265.39 discount

UndervaluedFair: $276.19Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$277.36B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

QDEL1 strengths · Avg: 10.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Areas to Watch

MRK4 concerns · Avg: 3.3/10
P/E RatioValuation
31.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
5.282/10

Expensive relative to growth rate

QDEL4 concerns · Avg: 3.0/10
PEG RatioValuation
2.064/10

Expensive relative to growth rate

Market CapQuality
$734.42M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.463/10

Elevated debt levels

Return on EquityProfitability
-49.9%2/10

ROE of -49.9% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : QDEL

The strongest argument for QDEL centers on Price/Book.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Bear Case : QDEL

The primary concerns for QDEL are PEG Ratio, Market Cap, Debt/Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while QDEL is a turnaround play — different risk/reward profiles.

QDEL carries more volatility with a beta of 0.74 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 40/100). QDEL offers better value entry with a 89.6% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Quidel Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for infectious disease, cardiology, thyroid, general and women's health, eye health, gastrointestinal disease, and toxicology applications globally. The company is headquartered in San Diego, California.

Visit Website →

Want to dig deeper into these stocks?